The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

By Michelle J. Khan, P. Castle, A. Lorincz, S. Wacholder, M. Sherman, David R. Scott, B. Rush, A. Glass, Mark Schiffman. Journal of the National Cancer Institute, 2005

1,188 citations recorded by the source corpus.

Subfields: Epidemiology, Obstetrics and Gynecology, Otorhinolaryngology

View Paper: https://www.semanticscholar.org/paper/f0faf783d58e6f94ed28652b096c7288914565bb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Luisa Lina Villa
2. A. Moscicki
3. S. Kjaer
4. Mark Schiffman
5. M. Stanley
6. E. Burd

In Obstetrics and Gynecology

1. E. Burd

Citations in the corpus

• 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. (2007, methodology): “Identical results have been reported for women 30 years of age and older in Portland, OR.(73)”
• Chapter 5: Updating the natural history of HPV and anogenital cancer. (2006, background): “In fact, HPV type is arguably more important han the presence or absence of mild microscopic evidence f infection in the prediction of risk of cancer [3] because oncarcinogenic types also frequently cause cytologic nd histologic abnormalities, whereas HPV type predicts utcome.”
• iArc monogrAphs on the evAluAtion oF cArcinogenic risks to humAns (2012, methodology): “Only sparse type-specific prospective data is available on the carcinogenicity of the full range of individual HPV genotypes (Khan et al., 2005; Schiffman et al., 2005; Wheeler et al., 2006).”